Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Long-Term Deferred Tax (2021)

Allogene Therapeutics' Long-Term Deferred Tax history spans 1 years, with the latest figure at $194.7 million for Q4 2020.

  • For Q4 2020, Long-Term Deferred Tax changed N/A year-over-year to $194.7 million; the TTM value through Dec 2020 reached $194.7 million, changed N/A, while the annual FY2020 figure was $194.7 million, N/A changed from the prior year.
  • Long-Term Deferred Tax for Q4 2020 was $194.7 million at Allogene Therapeutics.
  • Across five years, Long-Term Deferred Tax topped out at $194.7 million in Q4 2020 and bottomed at $194.7 million in Q4 2020.